BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 28485764)

  • 21.
    Pissa M; Helkkula T; Appelqvist F; Silander G; Borg Å; Pettersson J; Lapins J; Nielsen K; Höiom V; Helgadottir H
    Acta Oncol; 2021 Jul; 60(7):888-896. PubMed ID: 33945383
    [No Abstract]   [Full Text] [Related]  

  • 22. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants.
    Puntervoll HE; Yang XR; Vetti HH; Bachmann IM; Avril MF; Benfodda M; Catricalà C; Dalle S; Duval-Modeste AB; Ghiorzo P; Grammatico P; Harland M; Hayward NK; Hu HH; Jouary T; Martin-Denavit T; Ozola A; Palmer JM; Pastorino L; Pjanova D; Soufir N; Steine SJ; Stratigos AJ; Thomas L; Tinat J; Tsao H; Veinalde R; Tucker MA; Bressac-de Paillerets B; Newton-Bishop JA; Goldstein AM; Akslen LA; Molven A
    J Med Genet; 2013 Apr; 50(4):264-70. PubMed ID: 23384855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients.
    Dalmasso B; Pastorino L; Ciccarese G; Andreotti V; Grillo F; Mastracci L; Spagnolo F; Ballestrero A; Queirolo P; Bruno W; Ghiorzo P
    J Am Acad Dermatol; 2019 May; 80(5):1263-1271. PubMed ID: 30274933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis.
    Fargnoli MC; Gandini S; Peris K; Maisonneuve P; Raimondi S
    Eur J Cancer; 2010 May; 46(8):1413-20. PubMed ID: 20189796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family.
    Maubec E; Chaudru V; Mohamdi H; Blondel C; Margaritte-Jeannin P; Forget S; Corda E; Boitier F; Dalle S; Vabres P; Perrot JL; Lyonnet DS; Zattara H; Mansard S; Grange F; Leccia MT; Vincent-Fetita L; Martin L; Crickx B; Joly P; Thomas L; ; Bressac-de Paillerets B; Avril MF; Demenais F
    J Am Acad Dermatol; 2012 Dec; 67(6):1257-64. PubMed ID: 22841127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumours associated with BAP1 mutations.
    Murali R; Wiesner T; Scolyer RA
    Pathology; 2013 Feb; 45(2):116-26. PubMed ID: 23277170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population.
    Landi MT; Kanetsky PA; Tsang S; Gold B; Munroe D; Rebbeck T; Swoyer J; Ter-Minassian M; Hedayati M; Grossman L; Goldstein AM; Calista D; Pfeiffer RM
    J Natl Cancer Inst; 2005 Jul; 97(13):998-1007. PubMed ID: 15998953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
    Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
    Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Germline BAP1 alterations in familial uveal melanoma.
    Rai K; Pilarski R; Boru G; Rehman M; Saqr AH; Massengill JB; Singh A; Marino MJ; Davidorf FH; Cebulla CM; H Abdel-Rahman M
    Genes Chromosomes Cancer; 2017 Feb; 56(2):168-174. PubMed ID: 27718540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [From gene to disease; from p16 to melanoma].
    Gruis NA; Bergman W
    Ned Tijdschr Geneeskd; 2000 Oct; 144(44):2100-2. PubMed ID: 11103670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pediatric melanoma in melanoma-prone families.
    Goldstein AM; Stidd KC; Yang XR; Fraser MC; Tucker MA
    Cancer; 2018 Sep; 124(18):3715-3723. PubMed ID: 30207590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ocular melanoma and the BAP1 hereditary cancer syndrome: implications for the dermatologist.
    Martorano LM; Winkelmann RR; Cebulla CM; Abdel-Rahman MH; Campbell SM
    Int J Dermatol; 2014 Jun; 53(6):657-63. PubMed ID: 24697775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families.
    Njauw CN; Kim I; Piris A; Gabree M; Taylor M; Lane AM; DeAngelis MM; Gragoudas E; Duncan LM; Tsao H
    PLoS One; 2012; 7(4):e35295. PubMed ID: 22545102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases.
    Helgadottir H; Höiom V; Tuominen R; Nielsen K; Jönsson G; Olsson H; Hansson J
    J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27287845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature.
    Haugh AM; Njauw CN; Bubley JA; Verzì AE; Zhang B; Kudalkar E; VandenBoom T; Walton K; Swick BL; Kumar R; Rana HQ; Cochrane S; McCormick SR; Shea CR; Tsao H; Gerami P
    JAMA Dermatol; 2017 Oct; 153(10):999-1006. PubMed ID: 28793149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Single Center Retrospective Review of Patients from Central Italy Tested for Melanoma Predisposition Genes.
    De Simone P; Bottillo I; Valiante M; Iorio A; De Bernardo C; Majore S; D'Angelantonio D; Valentini T; Sperduti I; Piemonte P; Eibenschutz L; Ferrari A; Carbone A; Buccini P; Paiardini A; Silipo V; Frascione P; Grammatico P
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33322357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.
    Begg CB; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Mitra N; Busam K; From L; Berwick M;
    J Natl Cancer Inst; 2005 Oct; 97(20):1507-15. PubMed ID: 16234564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Germline versus Somatic BAP1 Mutations for Risk of Metastasis in Uveal Melanoma.
    Ewens KG; Lalonde E; Richards-Yutz J; Shields CL; Ganguly A
    BMC Cancer; 2018 Nov; 18(1):1172. PubMed ID: 30477459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group.
    Soufir N; Avril MF; Chompret A; Demenais F; Bombled J; Spatz A; Stoppa-Lyonnet D; Bénard J; Bressac-de Paillerets B
    Hum Mol Genet; 1998 Feb; 7(2):209-16. PubMed ID: 9425228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas.
    Helsing P; Nymoen DA; Ariansen S; Steine SJ; Maehle L; Aamdal S; Langmark F; Loeb M; Akslen LA; Molven A; Andresen PA
    Genes Chromosomes Cancer; 2008 Feb; 47(2):175-84. PubMed ID: 18023021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.